Tone mix
Week by week 52 weeks
Share of Cytokinetics Inc.'s 373 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 7, 2026 · tone +99Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?+83
- Week of Dec 22, 2025 · tone +62Health: US FDA approves Cytokinetics' heart disease drug+66
- Week of Jan 19, 2026 · tone +100Cytokinetics' (CYTK) Outperform Rating Reaffirmed at Royal Bank Of Canada+60
- Week of Nov 24, 2025 · tone +47Rep. Gilbert Ray Cisneros, Jr. Buys Cytokinetics, Incorporated (NASDAQ:CYTK) Stock+59
- Week of Dec 29, 2025 · tone +48The Year-End 2025 Biotech Rally And What It Means For 2026 - Cytokinetics (NASDAQ:CYTK), EyePoint (NASDAQ:EYPT)+45
- Week of Feb 9, 2026 · tone +96Cytokinetics Gets 'On Track' With Campaign For Cardio Condition+40
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Cytokinetics Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 5 | +19 |
| Last 30 sessions | 27 | +11 |
| Last 90 sessions | 66 | +12 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 1 outletCytokinetics (CYTK) Q3 2026 Earnings Call TranscriptNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
3 headlines, average tone +32: 1 positive, 2 neutral and 0 negative. Showing all 3.
- seekingalpha.com · 1 outletCytokinetics outlines >50% new-to-brand share goal by year-end as MYQORZO expands into the U.K. this quarter (NASDAQ:CYTK)Positive
- www.themarketsdaily.com · 1 outletFinancial Analysis: Cytokinetics (CYTK) and Its CompetitorsNeutral
- www.themarketsdaily.com · 1 outletCytokinetics (NASDAQ:CYTK) Announces Earnings ResultsNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Cytokinetics outlines >50% new-to-brand share goal by year-end as MYQORZO expands into the U.K. this quarter (NASDAQ:CYTK) | seekingalpha.com | 1 | Positive |
| Financial Analysis: Cytokinetics (CYTK) and Its Competitors | www.themarketsdaily.com | 1 | Neutral |
| Cytokinetics (NASDAQ:CYTK) Announces Earnings Results | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletCytokinetics (NASDAQ:CYTK) EVP Sells $220,255.00 in StockNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Cytokinetics (NASDAQ:CYTK) EVP Sells $220,255.00 in Stock | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletAnalyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
3 headlines, average tone 0: 1 positive, 1 neutral and 1 negative. Showing all 3.
- www.themarketsdaily.com · 1 outletCytokinetics (NASDAQ:CYTK) Stock Rating Lowered by Wall Street ZenNegative
- www.themarketsdaily.com · 1 outletCytokinetics' (CYTK) "Buy" Rating Reiterated at HC WainwrightPositive
- www.manilatimes.net · 1 outletCytokinetics to Announce Third Quarter Results on November 4, 2026Neutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Cytokinetics (NASDAQ:CYTK) Stock Rating Lowered by Wall Street Zen | www.themarketsdaily.com | 1 | Negative |
| Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright | www.themarketsdaily.com | 1 | Positive |
| Cytokinetics to Announce Third Quarter Results on November 4, 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Cytokinetics Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.